Clinical Trials
217
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (133 trials with phase data)• Click on a phase to view related trials
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 215
- Registration Number
- NCT07185373
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, China
🇨🇳Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
- Conditions
- Myasthenia Gravis
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT07146425
- Locations
- 🇨🇳
Huashan Hospital, affiliated to Fudan University, Shanghai, China
Comparative Study of a 1064-nm Fractional Picosecond Laser Versus IPL in Facial Rejuvenation
- Conditions
- Skin AgingSkin RejuvenationPhotoaging
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT07122310
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China
- Conditions
- Acute Respiratory Infections (ARIs)
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 28800
- Registration Number
- NCT07075029
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
🇨🇳Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage
- Conditions
- Cerebral Amyloid AngiopathyIntracerebral Hemorrhage Lobar
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT07026994
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
🇨🇳Huashan Hospital, Fudan University, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 44
- Next
News
Bio-Thera's BAT4406F Achieves Early Trial Success in Rare Neurological Disorder NMOSD
Bio-Thera Solutions' BAT4406F, an ADCC-enhanced anti-CD20 monoclonal antibody, demonstrated statistically significant efficacy in treating neuromyelitis optica spectrum disorder (NMOSD) during interim analysis of its pivotal Phase II/III trial.
Brain-Computer Interface Advances Enable Speech Synthesis and Action Control in Epilepsy Patient
A 43-year-old epilepsy patient with a brain tumor can now communicate and control actions through computer decoding of her thoughts, marking a significant BCI advancement.
Chinese BCI System Achieves Breakthrough in Language Decoding
A Chinese research team has achieved a breakthrough in brain-computer interface (BCI) technology using a domestically developed, invasive flexible BCI system.
Deep Brain Stimulation of Hippocampus Shows Promise for Treatment-Resistant Schizophrenia in New Trial
A crossover randomized controlled trial, DBS-HITS, is investigating deep brain stimulation (DBS) of the hippocampus for treatment-resistant schizophrenia.